Q3 2023 Results
Company overview
Financial review
Conclusions
Innovation: Pipeline overview
Financial performance
Cardiovascular
Immunology
Neuroscience
Ophthalmology
CoartemⓇ - PGH-1 (artemisinin combination therapy)
NCT04300309 CALINA (CCOA566B2307)
Malaria, uncomplicated (<5kg patients)
Phase 3
Indication
Phase
Patients
44
Primary
Artemether Cmax
Outcome
Measures
Arms
Intervention
Target
Patients
Experimental: artemether lumefantrine (2.5 mg:30 mg)
artemether lumefantrine (2.5 mg:30 mg) bid over 3 days, from 1-4 tablets per
dose
Infants and Neonates <5 kg body weight with acute uncomplicated plasmodium
falciparum malaria
2024
Readout
Milestone(s)
Publication
TBD
Appendix
Innovation: Clinical trials
Oncology
Global Health
References
Abbreviations
Other
83 Investor Relations | Q3 2023 Results
1 NOVARTIS | Reimagining MedicineView entire presentation